The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

نویسندگان

  • Nicholas G LaRocca
  • Lynn D Hudson
  • Richard Rudick
  • Dagmar Amtmann
  • Laura Balcer
  • Ralph Benedict
  • Robert Bermel
  • Ih Chang
  • Nancy D Chiaravalloti
  • Peter Chin
  • Jeffrey A Cohen
  • Gary R Cutter
  • Mat D Davis
  • John DeLuca
  • Peter Feys
  • Gordon Francis
  • Myla D Goldman
  • Emily Hartley
  • Raj Kapoor
  • Fred Lublin
  • Gary Lundstrom
  • Paul M Matthews
  • Nancy Mayo
  • Richard Meibach
  • Deborah M Miller
  • Robert W Motl
  • Ellen M Mowry
  • Rob Naismith
  • Jon Neville
  • Jennifer Panagoulias
  • Michael Panzara
  • Glenn Phillips
  • Ann Robbins
  • Matthew F Sidovar
  • Kathryn E Smith
  • Bjorn Sperling
  • Bernard Mj Uitdehaag
  • Jerry Weaver
چکیده

BACKGROUND The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was formed by the National MS Society to develop improved measures of multiple sclerosis (MS)-related disability. OBJECTIVES (1) To assess the current literature and available data on functional performance outcome measures (PerfOs) and (2) to determine suitability of using PerfOs to quantify MS disability in MS clinical trials. METHODS (1) Identify disability dimensions common in MS; (2) conduct a comprehensive literature review of measures for those dimensions; (3) develop an MS Clinical Data Interchange Standards Consortium (CDISC) data standard; (4) create a database of standardized, pooled clinical trial data; (5) analyze the pooled data to assess psychometric properties of candidate measures; and (6) work with regulatory agencies to use the measures as primary or secondary outcomes in MS clinical trials. CONCLUSION Considerable data exist supporting measures of the functional domains ambulation, manual dexterity, vision, and cognition. A CDISC standard for MS ( http://www.cdisc.org/therapeutic#MS ) was published, allowing pooling of clinical trial data. MSOAC member organizations contributed clinical data from 16 trials, including 14,370 subjects. Data from placebo-arm subjects are available to qualified researchers. This integrated, standardized dataset is being analyzed to support qualification of disability endpoints by regulatory agencies.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.

The need for improved clinical outcome measures in multiple sclerosis trials has been recognized for two decades, but only recently has the Food and Drug Administration (FDA) created a pathway for qualification of new clinician-reported outcome (ClinRO) assessments. Additionally, drug development in multiple sclerosis (MS) has been extraordinarily active, with numerous disease-modifying drugs n...

متن کامل

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis

Cognitive and motor performance measures are commonly employed in multiple sclerosis (MS) research, particularly when the purpose is to determine the efficacy of treatment. The increasing focus of new therapies on slowing progression or reversing neurological disability makes the utilization of sensitive, reproducible, and valid measures essential. Processing speed is a basic elemental cognitiv...

متن کامل

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with multiple sclerosis (MS). One of the MSOAC goals is acceptance and quali...

متن کامل

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis

Impaired manual dexterity is a frequently reported disability in people with multiple sclerosis (MS) and is increasingly prevalent with worsening disease. While various tests and patient-reported outcome measures are available, the Nine-Hole Peg Test (NHPT) is considered as a gold standard measure of manual dexterity and most frequently used in MS research and clinical practice. The MS Outcome ...

متن کامل

Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis

Low-contrast letter acuity (LCLA) has emerged as the leading outcome measure to assess visual disability in multiple sclerosis (MS) research. As visual dysfunction is one of the most common manifestations of MS, sensitive visual outcome measures are important in examining the effect of treatment. Low-contrast acuity captures visual loss not seen in high-contrast visual acuity (HCVA) measurement...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Multiple sclerosis

دوره   شماره 

صفحات  -

تاریخ انتشار 2017